Lower incidence of recorded cardiovascular outcomes in patients with type 2 diabetes using insulin aspart vs. those on human regular insulin: Observational evidence from general practices

Diabetes, Obesity and Metabolism

Volumn 15, Issue 4, 2013, Pages 358-363

  Rathmann, W ^a   Kostev, K ^b  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^b IQVIA   (United States)

Author keywords

Aspart; Insulin therapy; Micro and macrovascular outcomes

Indexed keywords

ACARBOSE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BIGUANIDE DERIVATIVE; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; FEMALE; GENERAL PRACTICE; GERMANY; GLYCEMIC CONTROL; HEALTH INSURANCE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; INCIDENCE; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PRESCRIPTION; SURVIVAL RATE;

EID: 84874302714     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12035     Document Type: Article

References (19)

1. DECODE Study Group. Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
2. Nakagami T, Qiao Q, Tuomilehto J et al. Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study. Eur J Cardiovasc Prev Rehabil 2006; 13: 555-561.
3. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95, 783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-240.
4. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005; 54: 1-7.
5. Perriello G, Pampanelli S, Porcellati F et al. Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial. Diabet Med 2005; 22: 606-611.
6. Rosenfalck AM, Thorsby P, Kjems L et al. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 2000; 37: 41-46.
7. Ceriello A, Quagliaro L, Catone B et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 2002; 25: 1439-1443.
8. Ceriello A, Cavarape A, Martinelli L et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med 2004; 21: 171-175.
9. Gallagher A, Home PD. The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes. Diabetes Res Clin Pract 2005; 67: 196-203.
10. Scognamiglio R, Negut C, de Kreutzenberg SV, Tiengo A, Avogaro A. Effects of different insulin regimes on postprandial myocardial perfusion defects in type 2 diabetic patients. Diabetes Care 2006; 29: 95-100.
11. Pollock RF, Valentine WJ, Pilgaard T, Nishimura H. The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective. J Med Econ 2011; 14: 36-46.
12. Becher H, Kostev K, Schröder-Bernhardi D. Validity and representativeness of the Disease Analyzer patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 2009; 47: 617-626.
13. Quan H, Sundararajan V, Halfon P et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-1139.
14. Sourij H, Schmoelzer I, de Campo A et al. Non-glycemic effects of insulin therapy: a comparison between insulin aspart and regular human insulin during two consecutive meals in patients with type 2 diabetes. Eur J Endocrinol 2011; 165: 269-274.
15. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
16. Blak BT, Smith HT, Hards M, Curtis BH, Ivanyi T. Optimization of insulin therapy in patients with Type 2 diabetes mellitus: beyond basal insulin. Diabet Med 2012; 29: e13-e20.
17. McAlpine RR, Morris AD, Emslie-Smith A, James P, Evans JM. The annual incidence of diabetic complications in a population of patients with Type 1 and Type 2 diabetes. Diabet Med 2005; 22: 348-352.
18. Schramm TK, Gislason GH, Køber L et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008; 117: 1945-1954.
19. Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther 2007; 82: 143-156.